PT Bio Farma To Build Blood Products Factory

BMI Core View: Drugmakers based in emerging markets will increasingly produce hard-to-manufacture pharmaceuticals. Firms in developing countries enjoy low operating costs but have traditionally lacked the expertise and machinery to make advanced therapeutics such as biologics. As economies in these non-traditional markets increase, capital will be released for the establishment of modern production facilities, with output destined for both domestic consumption and export.

To read the full article, please choose one of the following options: